The Beta-2 Agonist That Doesn't Stop Working — Tore Bengtsson

Every beta-2 agonist ever tested for muscle growth hits the same wall: desensitization. Dr. Tore Bengtsson built one that doesn't. A professor at Stockholm University and founder of Atrogi, Dr. Bengtsson has spent 25 years studying how beta-adrenergic receptors regulate metabolism, muscle, and brown fat. His lab developed 1,500+ compounds that activate beta-2 through distinct signaling pathways, and one is now heading into Phase 2 clinical trials. He shares how a "failed" experiment cracked the problem, why incretins only address half of metabolic disease problems, and what muscle loss after 50 means for drug discovery strategy. Key takeaways: Classical beta-2 agonists fail because desensitization shuts down the response Selectively activating specific signaling pathways from one receptor can produce entirely different outcomes Incretins reduce energy intake — but the energy expenditure side remains wide open The correlation between muscle mass and longevity is one of the most underserved areas in metabolic medicine 🔗 Dr. GPCR Ecosystem: 🎓 Membership & Pricing: 📰 Weekly News:

You can listen to The Beta-2 Agonist That Doesn't Stop Working — Tore Bengtsson online on Radio and Podcast. Open the player on this page to stream the available audio.

The Beta-2 Agonist That Doesn't Stop Working — Tore Bengtsson is an episode from Dr. GPCR Podcast by Dr. Yamina Berchiche.

This episode is 00:45:55 long.

This episode was published on May 6, 2026.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from Dr. GPCR Podcast when more episodes are available from the podcast feed.